Literature DB >> 17046580

Comparative generation and characterization of pluripotent unrestricted somatic stem cells with mesenchymal stem cells from human cord blood.

Gesine Kögler1, Sandra Sensken, Peter Wernet.   

Abstract

OBJECTIVE: Generation and expansion of pluripotent unrestricted somatic stem cells (USSCs) and mesenchymal cells (MSCs) from human cord blood as well their functional characterization were assessed.
METHODS: USSC generation was initiated from fresh and cryopreserved cord blood (CB). Culture conditions and functional assays distinguishing between USSCs and MSCs (e.g., endodermal differentiation) are described.
RESULTS: USSC cultures were initiated from 573 placental CB samples with a total generation frequency of 35.4% (n = 203), whereas successful generation of USSCs from cryopreserved products was scare. Medium, dexamethasone, and the fetal calf serum source are the major parameters to generate and expand the cells in a pluripotent state (osteogeneic, neural, and endodermal differentiation).
CONCLUSIONS: USSC or MSC cultures can be easily obtained from fresh CB samples, good manufacturing practice production of such cells is feasible. These USSCs or MSCs from CB, when matched for HLA antigens, may serve as an allogeneic stem cell source for the development of cellular therapy for tissue repair.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046580     DOI: 10.1016/j.exphem.2006.07.011

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  35 in total

1.  Effective combination of aligned nanocomposite nanofibers and human unrestricted somatic stem cells for bone tissue engineering.

Authors:  Behnaz Bakhshandeh; Masoud Soleimani; Nasser Ghaemi; Iman Shabani
Journal:  Acta Pharmacol Sin       Date:  2011-04-25       Impact factor: 6.150

2.  Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art.

Authors:  Arianna Malgieri; Eugenia Kantzari; Maria Patrizia Patrizi; Stefano Gambardella
Journal:  Int J Clin Exp Med       Date:  2010-09-07

Review 3.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

Review 4.  Cord blood--an alternative source for bone regeneration.

Authors:  Marcus Jäger; Christoph Zilkens; Bernd Bittersohl; Rüdiger Krauspe
Journal:  Stem Cell Rev Rep       Date:  2009-08-04       Impact factor: 5.739

5.  Clinical Protocols for the Isolation and Expansion of Mesenchymal Stromal Cells.

Authors:  Karen Bieback; Katharina Schallmoser; Harald Klüter; Dirk Strunk
Journal:  Transfus Med Hemother       Date:  2008-07-17       Impact factor: 3.747

6.  [Mesenchymal stem cells and their interaction with biomaterials: potential applications in tissue engineering].

Authors:  R K Schneider; R Knüchel; S Neuss
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

Review 7.  Fetal endothelial and mesenchymal progenitors from the human term placenta: potency and clinical potential.

Authors:  Abbas Shafiee; Nicholas M Fisk; Dietmar W Hutmacher; Kiarash Khosrotehrani; Jatin Patel
Journal:  Stem Cells Transl Med       Date:  2015-03-13       Impact factor: 6.940

8.  Induction of differentiation by down-regulation of Nanog and Rex-1 in cord blood derived unrestricted somatic stem cells.

Authors:  Lida Langroudi; Mehdi Forouzandeh; Masoud Soleimani; Amir Atashi; Azadeh Fahim Golestaneh
Journal:  Mol Biol Rep       Date:  2013-05-10       Impact factor: 2.316

9.  Enhancing ex vivo expansion of cord blood-derived unrestricted somatic stem cells for clinical applications.

Authors:  Z Demerdash; H El Baz; F Mahmoud; S Mohamed; K Maher; T Gaafar; S Shawky; M Hassan; D Abdelhady; T Taha
Journal:  Cell Prolif       Date:  2013-12       Impact factor: 6.831

Review 10.  Cord blood stem cells: a review of potential neurological applications.

Authors:  David T Harris
Journal:  Stem Cell Rev       Date:  2008-08-05       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.